BCYC - Bicycle Therapeutics Plc - ADR
IEX Last Trade
21.515
-0.145 -0.674%
Share volume: 63,602
Last Updated: Fri 30 Aug 2024 09:59:21 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$21.66
-0.15
-0.67%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-04 | 2022-11-03 | 2023-02-28 | 2023-05-04 | 2023-08-03 | 2023-11-02 | 2024-02-20 | 2024-05-02 | |
| Assets | |||||||||
| Total Assets | 445.482 M | 417.148 M | 410.609 M | 428.801 M | 454.170 M | 638.683 M | 595.344 M | 547.143 M | |
| Current Assets | 408.493 M | 381.285 M | 369.383 M | 381.253 M | 408.430 M | 603.036 M | 561.868 M | 515.962 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 9.454 M | 8.448 M | 9.022 M | 10.926 M | 10.023 M | 13.673 M | 11.406 M | 19.903 M | |
| Short Term Investments | 9.454 M | 8.448 M | 9.022 M | 10.926 M | 10.023 M | 13.673 M | 11.406 M | 19.903 M | |
| Total Receivables | 26.270 M | 11.368 M | 21.207 M | 76.512 M | 57.974 M | 17.277 M | 24.039 M | 39.062 M | |
| Current Cash | 372.769 M | 361.469 M | 339.154 M | 293.815 M | 340.433 M | 572.086 M | 526.423 M | 456.997 M | |
| Total Non-current Assets | 36.989 M | 35.863 M | 41.226 M | 47.548 M | 45.740 M | 35.647 M | 33.476 M | 31.181 M | |
| Property Plant Equipment | 16.815 M | 16.220 M | 19.110 M | 18.261 M | 17.572 M | 15.599 M | 14.515 M | 12.788 M | |
| Other Assets | 20.174 M | 19.643 M | 22.116 M | 29.287 M | 28.168 M | 20.048 M | 18.961 M | 18.393 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 445.482 M | 417.148 M | 410.609 M | 428.801 M | 454.170 M | 638.683 M | 595.344 M | 547.143 M | |
| Total liabilities | 134.090 M | 127.674 M | 139.826 M | 185.638 M | 234.073 M | 222.661 M | 224.412 M | 191.095 M | |
| Total current liabilities | 41.341 M | 41.552 M | 53.342 M | 52.995 M | 72.266 M | 69.736 M | 69.537 M | 49.510 M | |
| Accounts Payable | 4.859 M | 7.057 M | 6.472 M | 2.813 M | 5.250 M | 8.493 M | 13.050 M | 7.061 M | |
| Other liabilities | 50.109 M | 44.893 M | 45.284 M | 87.832 M | 119.413 M | 111.898 M | 114.795 M | 102.735 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 42.640 M | 41.229 M | 41.200 M | 44.811 M | 42.394 M | 41.027 M | 40.080 M | 38.850 M | |
| Other liabilities | 50.109 M | 44.893 M | 45.284 M | 87.832 M | 119.413 M | 111.898 M | 114.795 M | 102.735 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 311.392 M | 289.474 M | 270.783 M | 243.163 M | 220.097 M | 416.022 M | 370.932 M | 356.048 M | |
| Common stock | 29.649 M | 29.676 M | 29.713 M | 30.002 M | 30.192 M | 39.576 M | 42.600 M | 42.560 M | |
| Retained earnings | -272.771 M | -301.118 M | -331.096 M | -370.160 M | -412.763 M | -462.661 M | -511.760 M | -538.323 M |